FXS 7553
Alternative Names: EXPD-101; FXS-7553; XH-S004Latest Information Update: 21 Aug 2026
At a glance
- Originator S-Infinity Pharmaceuticals
- Developer Expedition Therapeutics; S-Infinity Pharmaceuticals
- Class Antibronchitics; Small molecules
- Mechanism of Action Cathepsin C inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bronchiectasis; Chronic obstructive pulmonary disease
Most Recent Events
- 13 Aug 2026 Phase-II clinical trials in Chronic obstructive pulmonary disease in China (PO)
- 05 Aug 2026 Pharmacokinetics and adverse events data from a phase-I trial in Bronchiectasis (In volunteers) released by Expedition Therapeutics
- 14 Jul 2026 Phase-II clinical trials in Bronchiectasis in China (PO) (Shanghai Fosun Pharmaceutical pipeline, July 2026) (NCT06981091)